335 related articles for article (PubMed ID: 17313998)
1. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.
McKenzie R; Bourgeois AL; Frech SA; Flyer DC; Bloom A; Kazempour K; Glenn GM
Vaccine; 2007 May; 25(18):3684-91. PubMed ID: 17313998
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.
Glenn GM; Villar CP; Flyer DC; Bourgeois AL; McKenzie R; Lavker RM; Frech SA
Infect Immun; 2007 May; 75(5):2163-70. PubMed ID: 17261601
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.
Behrens RH; Cramer JP; Jelinek T; Shaw H; von Sonnenburg F; Wilbraham D; Weinke T; Bell DJ; Asturias E; Pauwells HL; Maxwell R; Paredes-Paredes M; Glenn GM; Dewasthaly S; Stablein DM; Jiang ZD; DuPont HL
Lancet Infect Dis; 2014 Mar; 14(3):197-204. PubMed ID: 24291168
[TBL] [Abstract][Full Text] [Related]
4. Significance of Enterotoxigenic Escherichia coli (ETEC) Heat-Labile Toxin (LT) Enzymatic Subunit Epitopes in LT Enterotoxicity and Immunogenicity.
Huang J; Duan Q; Zhang W
Appl Environ Microbiol; 2018 Aug; 84(15):. PubMed ID: 29802193
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
[TBL] [Abstract][Full Text] [Related]
6. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.
Yu J; Cassels F; Scharton-Kersten T; Hammond SA; Hartman A; Angov E; Corthésy B; Alving C; Glenn G
Infect Immun; 2002 Mar; 70(3):1056-68. PubMed ID: 11854183
[TBL] [Abstract][Full Text] [Related]
7. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
[TBL] [Abstract][Full Text] [Related]
9. A tripartite fusion, FaeG-FedF-LT(192)A2:B, of enterotoxigenic Escherichia coli (ETEC) elicits antibodies that neutralize cholera toxin, inhibit adherence of K88 (F4) and F18 fimbriae, and protect pigs against K88ac/heat-labile toxin infection.
Ruan X; Liu M; Casey TA; Zhang W
Clin Vaccine Immunol; 2011 Oct; 18(10):1593-9. PubMed ID: 21813665
[TBL] [Abstract][Full Text] [Related]
10. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
Byrd W; Boedeker EC
Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Characterization of Immunogenicity and Efficacy against Diarrhea from MecVax, a Multivalent Enterotoxigenic E. coli Vaccine Candidate.
Seo H; Garcia C; Ruan X; Duan Q; Sack DA; Zhang W
Infect Immun; 2021 Jun; 89(7):e0010621. PubMed ID: 33875477
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin.
Luo Q; Vickers TJ; Fleckenstein JM
Clin Vaccine Immunol; 2016 Jul; 23(7):628-37. PubMed ID: 27226279
[TBL] [Abstract][Full Text] [Related]
13. Passive antibodies derived from intramuscularly immunized toxoid fusion 3xSTa
Nandre RM; Duan Q; Wang Y; Zhang W
Vaccine; 2017 Jan; 35(4):552-556. PubMed ID: 28017433
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
Lapa JA; Sincock SA; Ananthakrishnan M; Porter CK; Cassels FJ; Brinkley C; Hall ER; van Hamont J; Gramling JD; Carpenter CM; Baqar S; Tribble DR
Clin Vaccine Immunol; 2008 Aug; 15(8):1222-8. PubMed ID: 18579693
[TBL] [Abstract][Full Text] [Related]
15. The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine.
Jones FR; Hall ER; Tribble D; Savarino SJ; Cassels FJ; Porter C; Meza R; Nunez G; Espinoza N; Salazar M; Luckett R; Scott D
Vaccine; 2006 May; 24(18):3786-92. PubMed ID: 16343702
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX®) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
Sukwa N; Mubanga C; Hatyoka LM; Chilyabanyama ON; Chibuye M; Mundia S; Munyinda M; Kamuti E; Siyambango M; Badiozzaman S; Bosomprah S; Carlin N; Kaim J; Sjöstrand B; Simuyandi M; Chilengi R; Svennerholm AM
Vaccine; 2023 Nov; 41(46):6884-6894. PubMed ID: 37838479
[TBL] [Abstract][Full Text] [Related]
17. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.
Turner AK; Beavis JC; Stephens JC; Greenwood J; Gewert C; Thomas N; Deary A; Casula G; Daley A; Kelly P; Randall R; Darsley MJ
Infect Immun; 2006 Feb; 74(2):1062-71. PubMed ID: 16428753
[TBL] [Abstract][Full Text] [Related]
18. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico.
Sack DA; Shimko J; Torres O; Bourgeois AL; Francia DS; Gustafsson B; Kärnell A; Nyquist I; Svennerholm AM
Vaccine; 2007 May; 25(22):4392-400. PubMed ID: 17448578
[TBL] [Abstract][Full Text] [Related]
19. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.
McKenzie R; Bourgeois AL; Engstrom F; Hall E; Chang HS; Gomes JG; Kyle JL; Cassels F; Turner AK; Randall R; Darsley M; Lee C; Bedford P; Shimko J; Sack DA
Infect Immun; 2006 Feb; 74(2):994-1000. PubMed ID: 16428745
[TBL] [Abstract][Full Text] [Related]
20. Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes.
Evans DG; Evans DJ; Opekun AR; Graham DY
FEMS Microbiol Immunol; 1988 Dec; 1(3):117-25. PubMed ID: 3078739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
